US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

30.49 -0.78 (-2.49%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore Q2 Earnings Call Highlights ↗
Immunocore (NASDAQ:IMCR) reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV... 
Via MarketBeat
Topics Earnings
Immunocore (NASDAQ:IMCR) Q2 Revenue Beats but EPS Misses, Shares Tumble ↗
Via Chartmill
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore (IMCR) Q4 2025 Earnings Call Transcript ↗
Immunocore (IMCR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces R&D leadership evolution
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore (IMCR) Q2 2025 Earnings Call Transcript ↗
Immunocore (IMCR) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Growth Picks: 3 Low-Cost Stocks That Could Double in Value ↗
Via MarketBeat
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore (IMCR) Q2 Revenue Jumps 30% ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growth ↗
Immunocore (IMCR) beat Q2 2025 estimates with $98M revenue (+30% YoY) and a narrower EPS loss. KIMMTRAK sales surged 32%, while pipeline progress and strong cash position ($882.8M) boosted investor... 
Via Chartmill
News headline image
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
From Immunocore Holdings plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >